Pharmaceutica Analytica Acta

Pharmaceutical & drug delivery technologies for effecient pain management

8^th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems

March 07-09, 2016 Madrid, Spain

Abeer Al-Ghananeem

Sulliven University College of Pharmacy, USA
Al-Zaytoonah University of Jordan College of Pharmacy, Jordan

Posters & Accepted Abstracts: Pharm Anal Acta

Abstract:

Breakthrough pain in cancer patients is a transitory exacerbation of pain experienced for a short period of time by the patient who has relatively stable and adequately controlled baseline pain. Transmucosal drug delivery through intranasal, sublingual, and buccal mucosa are considered an attractive routes to deliver breakthrough pain management medications. It avoids the hepatic first-pass clearance, which results in enhanced bioavailability and faster onset of drug action. The in-vivo pharmacokinetics of three breakthrough pain drugs has been evaluated in rabbis. Conscious rabbits were used, because anesthesia could impair the nasal mucociliary clearance and thereby allowing the formulations to remain in contact with the nasal mucosa for a longer time than would be normally expected without anesthesia. The same apply for the sublingual delivery to mimic the transient time in clinical use. In two separate experiments, the sublingual administration of Fentanyl and Oxycodone showed promising kinetic profiles, resulting in a rapid absorption with acceptable absolute bioavailability up to 82%. Factors such as formulation viscosity and drug moieties of salt versus free base were also evaluated in light of its effect on absolute bioavailability. Furthermore, Tetrahydrocannabenol (THC) intranasal delivery, also showed acceptable bioavailability comparable to the currently marketed soft gelatin capsules formulations, but irritation to nasal mucous membranes requires further drug formulation efforts to overcome this problem. With the increase demand on enhancing the quality of cancer patients�?? life, transmucosal delivery offers compelling opportunities to bring new safe and effective drugs to the market.

Biography :

Email: AAlghananeem@sullivan.edu